US OptionsDetailed Quotes

KRON250117P5000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Nov 14 15:02
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
    Jaguar8
    Jaguar8
    Oct 23 08:00
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
    Kronos Bio (NASDAQ: KRON) presented preclinical data from its p300 KAT inhibitor program for HPV-driven tumors at the EORTC-NCI-AACR Symposium. The research demonstrates that their p300 KAT inhibitor, KB-9558, effectively suppresses HPV oncogenes E6 and E7, which are critical for tumor growth. The inhibition leads to restoration of p53 and Rb tu...
    Jaguar8
    Jaguar8
    Oct 9 09:40
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
    Kronos Bio (Nasdaq: KRON) will present preclinical data on its p300 KAT inhibitor program for HPV-driven tumors at the EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 23-25, 2024. The company's p300 KAT inhibitor, KB-9558, shows promise in targeting HPV-driven cancers by selectively inhibiting viral oncoproteins E6 and E7.
    Key findings include:
    HP...
    Jaguar8
    Jaguar8
    Oct 7 07:55
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
    Kronos Bio has announced the selection of KB-7898, a p300 KAT inhibitor, as its first development candidate for autoimmune diseases, specifically targeting Sjögren’s disease. This candidate stems from Kronos Bio's proprietary discovery engine, which decodes complex transcription factor regulatory networks.
    Preclinical data for KB-7898 will be presented at ACR Convergence 2024. The d...
    Jaguar8
    Jaguar8
    Sep 25 07:56
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
    Kronos Bio (Nasdaq: KRON) will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at ACR Convergence 2024 in Washington, DC. The presentation, scheduled for November 18, 2024, will showcase how p300 KAT inhibitionmodulates multiple pro-inflammatory signaling pathways in chronic inflammatory diseases.
    The compa...
Read more